Daiichi Sankyo
Company type | Public KK (TYO: 4568) |
---|---|
Industry | Pharmaceutical |
Founded | 2005 (by merger) |
Headquarters | Tokyo, Japan |
Key people | Kiyoshi Morita, Chairman Takashi Shoda, President & CEO |
Revenue | ¥ 880,120 million JPY (FY 2007) |
¥ 97,660 million JPY (FY 2007) | |
Number of employees | 30,000 (2010) products = Pharmaceutical products |
Website | www.daiichisankyo.com |
Daiichi Sankyo Co., Ltd. (第一三共株式会社, Daiichi Sankyō Kabushiki-kaisha, TYO: 4568) is a Japan-based major pharmaceutical company, which ranks number 20 in the world in sales[1].
History
Daiichi Sankyo was established in 2005 through the merger of Sankyo Co., Ltd. (三共株式会社, Sankyō Kabushiki Kaisha) and Daiichi Pharmaceutical Co., Ltd. (第一製薬株式会社, Daiichi Seiyaku Kabushiki Kaisha), which were century-old pharmaceutical companies based in Japan.
Acquisitions
In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs unit of Astellas Pharma.
On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion. Ranbaxy's Malvinder Singh will remain CEO after the transaction.[2][3]
In June 2008, the company expressed intent to acquire U3 Pharma, which would contribute a therapeutic anti-HER3 antibody to the company's anticancer portfolio.[4]
On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, the Berkley CA based, venture-backed small molecule pharmaceutic start-up for $805 and an additional $130 in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (GSK licensed) drug. | title=Daiichi Sankyo Intends to Purchase U3 Pharma for Roughly $236M | url= | format=print[5]
Products of Daiichi Sankyo Group
Sankyo
- Benicar (olmesartan medoxomil)
- Mevalotin (pravastatin)
- Loxonin (loxoprofen)
- Olmetec (olmesartan)
- Captopril
- WelChol (colesevelam HCl)
- Effient (Prasugrel)
win bp piramal (olmesartan medoxomil)
- Panipenem
Daiichi Pharmaceutical
- Cravit (levofloxacin)
- Evoxac (cevimeline)
- FloxinOtic (ofloxacin)
- Gracevit (sitafloxacin, only sold in Japan)
Pipeline candidates
Select mid-stage and late-stage investigational candidates in Daiichi-Sankyo's pipeline include:
- CS-011 (rivoglitazone)—Type 2 Diabetes
- CS-1008—Oncology
- CS-8958 (Laninamivir)—Influenza
- DU-176b—Venous thromboembolism
- SUN-11031—Cachexia
References
- ^ http://pharmexec.findpharma.com/pharmexec/data/articlestandard//pharmexec/302008/531367/article.pdf
- ^ Daiichi to get 35% stake in Ranbaxy
- ^ The Brand Blog: Ranbaxy promoters to sell stake to Japan's Daiichi
- ^ staff (2008-06-15). Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. p. 8.
{{cite news}}
:|access-date=
requires|url=
(help); Missing or empty|title=
(help) - ^ "Daiichi Sankyo To Acquire Plexxiko". Retrieved 02/28/2011.
{{cite web}}
: Check date values in:|accessdate=
(help)
External links